← All Immunome INC filings

Immunome INC Schedule 13D activist filings

Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.

NASDAQ
IMNM
Immunome INC
SCHEDULE: Immunome Investor Stake Dips Below 5% After Equity Offering
Enavate Sciences and Immunome Aggregator report their beneficial ownership in Immunome, Inc. common stock has been diluted to 4.3% following a recent public equity offering.
NASDAQ
IMNM
Immunome INC
SCHEDULE 13D/A: Enavate Sciences Increases Stake in Immunome, Inc. to 6.0% Following Public Offering
Immunome Aggregator, LP, an entity managed by Enavate Sciences GP, LLC, has significantly increased its beneficial ownership in Immunome, Inc. to 6.0% through a recent purchase of shares in the Issuer's 2025 public offering.